SOETOMO SCORE AS A PREDICTOR OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS
DOI:
https://doi.org/10.61841/jvq92z92Keywords:
Soetomo score, Neurocognitive disorder, Prognostic testAbstract
Background HIV-Associated Neurocognitive Disorders (HAND) was one of the neurological complications of HIV infection. However, no biomarkers have been sufficiently validated for prognosis.
Objective: To develop a scoring system and determine prognostic values of the Soetomo Score as a Predictor of HIV-Associated Neurocognitive Disorders (SSP HAND).
Methods: The case-control study was performed at the UPIPI outpatient clinic. The examination is performed using MoCa-Ina.Eight parameters that were possible predictors of HAND were analyzed by bivariate and multivariate. Results were analyzed using a calibration test and a discrimination test to produce an Area Under Curve (AUC) value. The cut-off point could make identification of good and bad prognostics.
Results: The equation of SSP HAND was Y=-4.164+1.249 score total of SSP HAND. The AUC value of this score was 80.9% (95% CI=71.1%-90.6%). The value of SSP HAND was ≥3.5, which means that the sensitivity was 74.4% and the specificity was 79.5%. Subjects with scores 0–3 had good prognostic, while those with scores 4–5 had bad prognostic.
Conclusion: The value of SSP HAND ≥3.5 could make a good prediction of HAND.
Downloads
References
[1] Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, et al. Neurological complications of HIV infection in pre-HAART and HAART eras: a retrospective study. Journal of Neurology 2015;262:1317-1327.
[2] Ueda, S., Witaningrum, A.M., Khairunisa, S.Q., Nasronudin, Kameoka, M. Transmission dynamics of HIV-1 subtype B strains in Indonesia. Scientific Reports. 2019;9(1),13986
[3] Williams DW, Calderon TM, Lopez L, Carvallo-Torres L, Gaskill PJ, Eugenin EA, et al. Mechanisms of HIV Entry into the CNS: Increased Sensitivity of HIV-Infected CD14 + CD16 + Monocytes to CCL2 and Key Roles of CCR2, JAM-A, and ALCAM in Diapedesis. PLoS ONE 2013;8:e69270.
[4] Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV-associated neurocognitive disorders. Curr HIV Res 2014;12:85-96.
[5] Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, et al. Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology 2014;13:1139-1151.
[6] Cohen RA, Seider TR, Navia B. HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther 2015;7:37.
[7] Barnes DE, Covinsky KE, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting risk of dementia in older adults: The late-life dementia risk index. Neurology 2009;73:173-179.
[8] Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA. Midlife risk score for the prediction of dementia four decades later. Alzheimer's & Dementia 2014;10:562-570.
[9] Windarto, Anggriani, N. Global stability for a susceptible-infectious epidemic model with fractional incidence rate. Applied Mathematical Sciences. 2015;9(73-76), pp. 3775-3788
[10] Harnanti, D.V., Hidayati, A.N., Miftahussurur, M.Concomitant sexually transmitted diseases in patients with diagnosed HIV/AIDS: A retrospective study. African Journal of Infectious Disease. 2019; 12 (Special Issue 1), pp. 83-89
[11] Sinansari, R., Bambang Prajogo, E.W., and Widiyanti, P. In silico screening and biological evaluation of the compounds of justicia gendarussa leaf extract as interferon gamma inducer: A study of anti-human immunodeficiency virus (HIV) development. African Journal of Infectious Diseases. 2018;12(Special Issue 1), pp. 140-147
[12] Yunifiar, M.Q., Kotaki, T., Witaningrum, A.M., (...), Nasronudin, N., Kameoka, M. Sero- and Molecular Epidemiology of HIV-1 in Papua Province, Indonesia. Acta medica Indonesiana. 2017; 49(3), pp. 205-214
[13] Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, et al. Cardiovascular risk factors are associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010;75:864-873.
[14] Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a South Asian population—contextual application of the 2007 criteria. BMJ Open 2012;2:e000662.
[15] Cross S, Onen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol 2013;8:1114-1122.
[16] Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
[17] Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73:342-348.
[18] Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med 2010;11:642-649.
[19] Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008;24:1301-1307.
[20] Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (London, England) 2011;25.
[21] Levine AJ, Hinkin CH, Ando K, Santangelo G, Martinez M, Valdes-Sueiras M, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol 2008;30:836-843.
[22] Abdelgawad, M.A. Synthesis and antimicrobial evaluation of N-(3-benzoxazol-2-yl-phenyl) (2018) International Journal of Pharmaceutical Research, 10 (4), pp. 461-465. https://www.scopus.com/inward/record.uri?eid=2-s2.0-
85062387451&doi=10.31838%2fijpr%2f2018.10.04.070&partnerID=40&md5=269cbd06296ddff14baa9c45d72e7e33
[23] Pinzon, r. T. & sanyasi, . R. D. L. R. (2018) is there any benefit of citicoline for acute ischemic stroke ? Systematic review of current evidences. Journal of Critical Reviews, 5 (3), 11-14. doi:10.22159/jcr.2018v5i3.24568
[24] Patel RR, Patel JK. "Novel Technologies of Oral Controlled Release Drug Delivery System." Systematic Reviews in Pharmacy 1.2 (2010), 128-132. Print. doi:10.4103/0975-8453.75054
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
